Literature DB >> 10717724

Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain.

G Zeppetella1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10717724     DOI： 10.1191/026921600668793500

Source DB:  PubMed          Journal:  Palliat Med        ISSN： 0269-2163            Impact factor:   4.762


× No keyword cloud information.
  5 in total

Review 1.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?

Authors:  Kristin Moksnes; Olav M Fredheim; Pål Klepstad; Stein Kaasa; Anders Angelsen; Turid Nilsen; Ola Dale
Journal:  Eur J Clin Pharmacol       Date:  2008-01-06       Impact factor: 2.953

3.  Role of intranasal fentanyl in breakthrough pain management in cancer patients.

Authors:  Wojciech Leppert
Journal:  Cancer Manag Res       Date:  2010-09-30       Impact factor: 3.989

4.  Recent advances in the use of opioids for cancer pain.

Authors:  Joanne Droney; Julia Riley
Journal:  J Pain Res       Date:  2009-09-23       Impact factor: 3.133

5.  Rapid acting fentanyl formulations in breakthrough pain in cancer. Drug selection by means of the System of Objectified Judgement Analysis.

Authors:  Robert Janknegt; Marieke van den Beuken; Sjouke Schiere; Michael Überall; Roger Knaggs; Jaquie Hanley; Morten Thronaes
Journal:  Eur J Hosp Pharm       Date:  2017-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.